DEPARTMENT OF THE AIR FORCE AIR FORCE RESEARCH LABORATORY WRIGHT-PATTERSON AIR FORCE BASE OHIO 45433
SUBJECT: Comments for the update to the ATSDR Toxicological Profile for JP-5 and JP-8 occurring in FY14.
1. Executive Summary 1.1 Purpose. To provide information to supplement the FY14 update of the ATSDR Toxicological Profile for JP-5 and JP-8, and to present recommendations for data inclusion.
1.2 Conclusions. The authors conclude that the exposure compounds and concentrations are unknown in studies published by the University of Arizona utilizing the DeVilbiss® Ultra-Neb nebulizer exposure system. Therefore these studies are unsuitable for assessment of JP-8 risk. ATSDR should not handle these studies as "key studies" in their FY14 update.
2. Toxicologists at 711 HPW/RHDJ have reviewed the 2013 document published by ATSDR entitled "Addendum to the Toxicological Profile for Jet Fuels (JP-5 and JP-8)" (ATSDR, 2013) . The full document "Toxicological Profile for JP -5 and JP-8", published in 1998 (ATSDR, 1998) , is scheduled for update in FY14. A review of the Addendum identified concerns over the quality of a subset of studies summarized in the 2013 document and the potential inclusion of this subset in the 2014 update.
2.1 References in this report are listed in Attachment A.
3. The primary purpose of this report is to provide further clarification on the scientific drawbacks of the study subset in question. In the mid-1990s, the University of Arizona (UA) Department of Pediatrics was awarded a Basic Research grant from the Air Force Office of Scientific Research (AFOSR). With these funds, the UA utilized an inhalation exposure system 1 Distribution A: Approved for public release; distribution unlimited. 88ABW-2013-5467 2 Distribution A: Approved for public release; distribution unlimited. 88ABW-2013-5467 at their laboratory for a series of basic research studies on the jet fuel JP-8. The UA published jet fuel studies from circa 1996 through circa 2008 using this system featuring a DeVilbiss® UltraNeb nebulizer for exposure atmosphere generation and a 7-stage IN-TOX® cascade impactor for exposure concentration characterization. A list of 20 UA studies utilizing this generation system that were included in the 2013 ATSDR Addendum can be found in Attachment B.
3.1. Please find attached the description of the UA exposure system authored by John Hinz (AFRL/RSRE) and Maj Robert B. Walton (RSHI) and dated 10 Jul 2002 as part of their trip report to the 9 th Annual Meeting of the AFOSR JP-8 Jet Fuel Toxicology Workshop (15 -17 May 2002) . The description of the exposure system begins on the fourth page of Attachment C. The description provides information unavailable from published accounts of the UA exposure system. 4. The UA studies are lacking in scientific merit in three areas that were identified in the 2013 Addendum and that have the potential to impact the FY14 update. First, unique requirements of using the DeVilbiss® Ultra-Neb nebulizer generation system with JP-8 resulted in undesirable inhalation exposure conditions. 4.1 Attachment C notes that plastic cups containing JP-8 were positioned above the nebulizer's ultrasonic generator to produce the JP-8 aerosol:vapor mixture. One-hour exposures were interrupted every 15 minutes in order for the cups to be replaced. 4.1.1 There is potential for the JP-8 vapor and aerosol mixture to contain minute particles of plastic if the plastic cups were disintegrated due to sonication. Alternatively, the JP-8 atmosphere may contain plastic components dissolved by JP-8. It is unclear if plastic contamination was ever evaluated.
4.1.2
The responses observed in UA studies (Attachment B) are potentially attributable to the chemical decomposition of plastic containers and subsequent nebulization of plasticizing chemicals into the inhalation chambers. Plasticizers are well-known lung and immune toxicants, resulting in endpoints similar to those seen in UA studies. The UA study by Wang et al. (2001) noted an increase in macrophages (ATSDR, 2013) . Similar increases are produced with exposure to the plasticizer mono-2-ethylhexyl phthalate (MEHP) (Larsen et al., 2004) . The Addendum summary of the UA study by Pfaff et al. (1996) reported thickening of bronchiole epithelium (ATSDR, 2013); similar results were found in rats following exposure to di-(2-ethylhexyl) phthalate (DEHP) aerosols by Klimisch et al. (1992) . 4.2 Therefore, considerable uncertainty exists regarding the content (potential co-exposure with plastic particles or plasticizer compounds) and consistency of the conditions to which 3 Distribution A: Approved for public release; distribution unlimited. 88ABW-2013-5467 animals were exposed throughout the many studies published by the UA while using this system (Appendix B). 4.2.1 A full description of this system is presented in Attachment C. It appears that much of this information is unavailable in published studies.
5. Second, exposure concentration characterization in the UA studies found in Attachment B was inadequate.
5.1 Attachment C describes the use of a cascade impactor to quantify aerosol concentration as an "uncommon approach". Cascade impactors are designed to measure aerosol size, not concentration. Recent attempts to utilize such a system to quantify JP-8 exposure resulted in underestimation of the aerosol concentration by at least 50 percent due to evaporation (Tremblay et al., 2011) .
5.1.1 UA researchers acknowledged the variability and inaccuracy of utilizing cascade impactors to measure jet fuel aerosol, due to the high volatility of the fuel and its ability to transition between aerosol and vapor states (Herrin et al., 2006) .
5.2
Vapor concentrations during the UA animal exposure studies were not measured. Instead, the body of work relied on gas chromatograph (GC) samples from impactor plate deposits taken during preliminary mock exposures (not during actual animal exposures). The average aerosol:vapor ratio was stated to be 1.5 (Hays et al., 1995) . This is the value also stated in 2002 (Attachment C) and again in 2011 (Hilgaertner et al.) .
5.2.1 An average aerosol:vapor ratio corresponds to an aerosol content of approximately 60 percent of the total exposure.
5.2.2
The use of a single aerosol:vapor ratio from initial trial/mock exposures to estimate total concentration is not expected to accurately describe multiple inhalation studies and study concentrations. The portion (percentage) of aerosol in a combined vapor and aerosol jet fuel exposure typically increases when the overall exposure concentration increases. Fully characterized exposures show aerosols ranging from 4.2 to 19 percent for Jet A concentrations of 500, 1000 and 2000 mg/m 3 in two 14-day inhalation studies (Sweeney et al., 2013) . The Jet A used in these studies was essentially JP-8 without the military additives and was generated with a Sonimist® ultrasonic spray nozzle.
5.2.3
The principle of increasing aerosol with increasing concentration holds true across fuels and generation methods. Aerosol percentages of 0.6 to 33 were measured for synthetic paraffinic kerosene (SPK) exposures of 200 to 2000 mg/m 3 (Mattie et al., 2011) . For another alternative jet fuel, Hydrolized Fatty Acids and Esters (HEFA) from a feedstock of mixed fatty acids (HEFA-F), aerosols ranged from 7 to 28 percent for HEFA-F exposures of 200 to 2000 mg/m 3 (Mattie et al., 2012) . Exposure concentrations were generated using commercial atomizers and were measured in two different laboratories.
5.3
The lack of adequate quantitation in the UA studies (Appendix B) alone undermines the validity of these studies. Additional quantitation deficits in these studies are discussed in Appendix C.
6. The third issue of scientific merit concerning the UA studies (Appendix B) stems from a 2011 publication which suggested incorrectly that the exposure concentrations in studies using the DeVilbiss® generation system may be "corrected" by multiplying the published aerosol concentration by a factor of 8. Hilgaertner et al. (2011) was able to correlate lung compliance measurements in mice exposed on their new Lovelace® jet nebulizer system to 1000 mg/m 3 JP-8 (6 to 10 percent aerosol) to lung compliance measurements in mice exposed to 125 mg/m 3 JP-8 (approximately 60% aerosol) using the DeVilbiss® system. The authors suggested that, since there was an 8-fold difference in concentration for this similar measurement of effect, all UA studies using the DeVilbiss® system may then be "corrected" by multiplying the aerosol concentration by a factor of 8.
6.1 There is no evidence that a single point correlation of effect (lung compliance in mice) will hold true over multiple studies, species or endpoints.
7. The authors would like to make some recommendations to ATSDR regarding the use of these UA studies (Appendix B) in the FY14 full toxicological profile update.
7.1 The ATSDR should include the UA studies in the reference list and should thoroughly discuss all shortcomings of these studies. No further use of the UA studies using the DeVilbiss system should be made, as the actual exposure contents and concentrations in these studies are unknown.
7.1.1 The ATSDR report in section 2.2.1 Inhalation Exposure discusses the UA studies performed with the DeVilbiss® Ultra-Neb nebulizer system (ATSDR, 2013). However, this discussion did not include the generation system's plastic cup issue (section 4 of this report).
7.2 If further mention of any of the UA studies list in Appendix B occurs in the full revised Toxicological Profile, a definitive footnote should be included to remind the reader of the inadequacies of these studies.
7.2.1 Although the ATSDR addressed the UA studies in their 2013 Addendum report in section 2.2.1 Inhalation Exposure and "noted whether the reported concentrations were for the aerosol component only or aerosol and vapor components" throughout the inhalation section, a reader interested only in immune response, for example, may not read the introductory materials and might miss the significance of the words "(aerosol component only)" behind the exposure concentration stated.
7.3 The ATSDR should not suggest that the UA studies concentrations may be "corrected" by using a factor of 8. Instead, ATSDR should discuss why a single point correlation of effect may not be applied across studies, endpoints and species. 7.3.1 Text in the 2013 ATSDR Addendum (section 2.2.1) states, "Although, Hilgaertner et al. (2011) and Herrin et al. (2006) estimated that the aerosol only concentrations represented only one-eighth of the total JP-8 exposure, ATSDR has not corrected the reported exposure concentration".
7. 4 The ATSDR should not consider as "key literature" the UA studies listed in Appendix B, when assessing the health effects of JP-8 in the FY14 full Toxicological Profile update.
7.4.1 Under section 2.2.1 Inhalation Exposure of the 2013 ATSDR Addendum, the UA studies listed in our Attachment B were summarized in their appropriate subsections (e.g., 2.2.1.2 Systemic Effects), alongside studies from other laboratories in which adequate and industry-accepted characterization of exposure conditions were performed. 7.4.2 The authors understand that the 2013 ATSDR Addendum followed the template and purpose of ATSDR Addenda. "The purpose of this addendum is to provide to the public and to federal, state, and local agencies a non-peer reviewed supplement of the scientific data that were published in the open peer-reviewed literature since the release of the profile in 1998" (ATSDR, 2013).
7.4.3 However, in effect, the ATSDR gave the listed UA studies, in which exposure is unknown, as much weight in their document as fully characterized studies in the 2013 Addendum.
7.4.4 Fortunately, the format and purpose of a full ATSDR Toxicological Profile is different. "Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented but is described in less detail than the key studies" (ATSDR, 2012) . Therefore, ATSDR is allowed to make distinctions between key literature and additional studies.
8. Further comments and recommendations to ATSDR regarding the FY14 full Toxicological Profile update are found in Attachment D. These comments/recommendations are independent of the primary purpose of this report, but should assist the ATSDR in completing their update. On the other hand, the AF's presentations were more applied than most. As Dr. Kozumbo reminded us all, AFOSR's research effort aims at disclosing the potentially toxic interactions between JP-8 and the biological tissues exposed to it as well as the mechanisms that mediate these interactions -an effort intended to contribute to and improve upon an integrated health risk assessment of this fuel. Attachments 1-3 present in order the workshop's agenda, list of attendees and executive summary of the meeting. Bound abstracts from the presentations are on file with RSRE.
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AFIERA's Presentations. Maj Walton briefed the Workshop on the results of the AF's "acute epidemiology study" that lead to the development of a new, tri-layered, fuel-resistant uniform for better protection of tank entry personnel (see Attachment 4).
Mr. Hinz described RSRE's project to characterize JP-8's potential for respiratory irritation and its successful application to the development of acute exposure guidelines by the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances (see Attachment 5) .
Industry's Participation. In addition to DoD's participation, building on concerns over JP-8's purported link to immunotoxic health effects voiced at AFIERA's second international conference on jet fuel, this workshop has begun to draw interest from industry. Dr. Cynthia Mann, an immunotoxicologist from ExxonMobil Biomedical Sciences, Inc., who has been brushing up on the literature in this area, attended the workshop. Dr. George Woodall (American Petroleum Institute) outlined (see his abstract) for the meeting's participants industry plans for its own examination of jet fuel's immunotoxicity. Unlike the apparent flexibility allowed in the academic research described at the workshop, industry's study design is obliged to follow more consistent protocols outlined in the U. S. EPA's "Health Effects Test Guidelines, OPPTS 870.7800, Immunotoxicity; EPA 712-C-98-351, Aug98". It was not clear whether the academic community understood these constraints. Most of the work at the University of Arizona has used mice, and tissues obtained from them, as the principle test system. Industry's protocol, a 28-day, EPA-defined dermal immunotox bioassay with Jet-A, will use rats (to add a second species to the data base) and include positive, negative and vehicle controls. The contract for this study has been awarded to ExxonMobil's laboratory; the study should start sometime in June'02.
Book Proposal. Dr. Witten urged the workshop to consider writing a book on JP-8's toxicology; he already has a publisher in mind. The workshop's participants would author chapters of this book, with Witten serving as the book's senior editor. There was support for the idea, although no final commitments or decisions were made. If this proposal develops legs, both industry and the military might consider preparing their own chapters for it.
Laboratory Tour. Dr. Witten graciously gave Mann, Walton and Hinz a guided tour of his laboratory at the Un. AZ's Health Science Center. A number of the studies described at this workshop used animals or tissues dosed and obtained from Witten's lab. Most real world exposure to JP-8 comes through the dermal or inhalation routes. Witten's laboratory chose the latter approach, exposing mice to atmospheres laden with a mixture of JP-8 aerosol and vapor. To date, the laboratory appears to have focused most of its attention on the aerosol fraction. Dr. Witten described the exposure system (it was on display in a laboratory fume hood) and some of the studies that have been done with it. The laboratory appears to be conducting inhalation studies with a sophisticated chamber system and conscientious personnel supported by limited analytical or technical resources. A summary based on what we heard and saw is presented in Attachment 6. We also plan to obtain copies of the published descriptions of the design and operation of the Un AZ exposure system. UNIVERSITY of ARIZONA / WITTEN EXPOSURE SYSTEM.
• Main Elements (see Figure 1 ) DeVilbiss Ultrasonic Nebulizer. This medical device, an ultrasonic humidifier used to introduce moisture into breathing air, has been adapted to generate a fuel aerosol that is gently purged from the device by fan-forced fresh air. A plastic cup, charged with ~15 mls of fuel, has been inserted over the ultrasonic generator. There is no direct connection between the generator and the exposure chamber.
Glass Beaker. Suspended over the gap between the ultrasonic generator and the chamber inlet, the beaker was recruited as a dilution and mixing vessel for the test atmosphere before the atmosphere is aspirated into the exposure chamber.
Multi-port, Nose-only Inhalation Exposure Chamber. Made of stainless steel, about the size and shape of an attaché case, this IN-TOX product will hold up to 24 mice, each contained in its own restraining tube. The restraining tubes, each sealed air tight to the chamber by an O-ring, plug into one side of the chamber. Seen end-on, the chamber is divided sagittally by an internal baffle, which is nippled to receive the nose cones of the restraining tubes. The chamber on one side of the baffle supports the tubes, while the opposite side serves as a supply plenum for the test atmosphere. The chamber's volume was stated to be 3 L; however, on inspection this appeared to represent the supply plenum. The animal's side of the chamber [another 3 L?] is operated at an exhaust rate of ~0.225 LPM to expel exhaled air; the supply plenum is exhausted at ~2 LPM.
Restraining Tubes. Lucite and plastic tubes, bunged to prevent escape, with a conical nosepiece. The tubes serve to limit/direct exposure to the nose and respiratory tract while minimizing dermal and oral intake of the test agent.
2 LPM Personal Sampling Pump. The pump aspirates air (thereby ventilating the chamber) laden with the test atmosphere from the nebulizer and beaker into and through the plenum side of the exposure chamber. Operating on the exhaust side of the system, it draws the atmosphere from the inhalation chamber and through a cascade impactor before expelling the air.
Cascade Impactor. Normally used to help characterize by inertial impaction the size distribution of an aerosol, this particular 7-stage device (made by IN-TOX) was also recruited to determine exposure concentration.
• System Operation As Dr. Witten described the system -we did not see it in operation -the ultrasonic humidifier/nebulizer creates a generous, turbulent cloud of aerosol that must be diluted before it is sucked into the exposure chamber. As explained to us, the inverted beaker and gaps in supply tubing (see Fig. 1 ) help to attenuate the atmosphere as it is drawn into the chamber. It is our supposition that while the output from an ultrasonic humidifier is apt to be turbulent, it is not evident how an open system such as theirs dampens the turbulence (it certainly dilutes the concentration), obtaining a more consistent exposure.
Each animal's restrainer penetrates the external port of the chamber, its nose cone applied to the small nipples in the chamber's internal baffle, the mouse receiving its breathing air from the plenum side of the system. It was not clear whether port-to-port variability in exposure concentration had been characterized. Except for the vent port on the animals' side of the baffle, the "3 L" chamber (actually just the supply plenum side of it) is ventilated at 2 LPM. Theoretically, at this volume and flow rate, the supply plenum should reach equilibration (t99) in ~6.9 minutes, ~12% of the total exposure time. This would not be unacceptably long, except that equilibration must be repeated three more times during each 1 hour exposure (see Fig 2 and discussion of plastic cups below).
All air drawn through the supply plenum exits through the cascade impactor. All determinations of chamber aerosol concentration depend on results obtained from the cascade impactor and are based gravimetrically on changes in weight of the collection plates contained within the instrument. This uncommon approach to concentration measurement may yield a time weighted average approximation of the aerosol content, but cannot reflect chamber equilibration or the constancy of chamber concentration during each exposure. The plates with the two heaviest deposits may be subjected post-exposure to GC analysis, although such analysis (it's expensive) does not appear to be routine. The lab's quantitation methods appear to overlook the volatiles obtained from the jet fuel, relying instead on initial chamber trials conducted some years ago that suggested then a mean aerosol to vapor ratio of ~1.5x.
Dr. Witten stated that the nebulizer's plastic cups, charged with 15 mls of jet fuel, do not last very long -they begin to disintegrate and have to be replaced every 15 minutes (they retrieve about 10 mls from the used cup) during a 1-hour exposure. Cup replacement, no matter how prompt, shuts the generation system down repeatedly and subdivides each exposure into four 15-minute increments. From our perspective, the exposure chamber must re-equilibrate with fresh test atmosphere each time the generation system is restarted. Witten attributed the cup's failure to the ultrasonic generator; but, the loss of the cup's integrity might also be due to the chemical action of the fuel. From his description, we were not sure whether his lab has assayed, fingerprinted and compared the original fuel with the cup's residue and the content of the chamber's atmosphere to ascertain which (if any) of the fuel's or the atmosphere's constituents have gained from or been lost to the plastic in the generation system.
• Assessments & Suggestions
The research projects of many participants at the Workshop depend on Dr. Witten's lab for animals and tissues dosed with JP-8. Published reports state that the lab has exposed rodents to levels ranging from 5 to 2500 mg/m3. The responses obtained from the animals tell us that they have been dosed during these exposures. However, since much of this research depends on one lab's efforts, the record of these exposures might benefit from a more thorough characterization of the test atmosphere and the exposure process. How faithfully did the test atmospheres represent the constituents of the original fuel? What constituents were present? Since all of JP-8 is at least to some degree volatile, how did the fuel partition between aerosol and vapor phases? How repeatable and stable were the exposure atmospheres -and the dosages that the animals received from them? These exposures ought to be fully and regularly characterized to identify which constituents (ideally all) of JP-8 are present in these test atmospheres and to verify that these atmospheres are faithfully reproduced each time.
Dr. Witten's lab built its inhalation facility around the IN-TOX chamber. We believe that this sophisticated system dates back some years to a time when radioactive aerosols were being studied. With limited quantities of a potentially dangerous and expensive material to work with then, a low volume, directed exposure system (the mice inhale the test atmosphere directly from a "nipple") made sense. These constraints do not apply now to jet fuel, which is readily available and comparatively nontoxic. A simpler chamber, perhaps modeled after the IN-TOX 16 Distribution A: Approved for public release; distribution unlimited. 88ABW-2013-5467 design to exploit the equipment at hand, but without the internal baffle and operated at higher flow rates, should be easier to work with. It would process enough test atmosphere to permit sufficient grab sampling to better characterize exposure concentration, stability and distribution within the chamber without compromising the dosing process. Grab samples should simultaneously capture both the aerosol and vapor phases of the test atmosphere, as both are present in these exposures. At least some samples should be fingerprinted to confirm whether all of JP-8's constituents are represented. Periodically, samples might be taken to characterize the size distribution, respirability and constituent composition vs size of any aerosol -a cascade impactor serves this assessment.
Periodic replacement of the nebulizer's cup during each exposure temporarily stops generation and delivery of the test atmosphere, leading to a variable, saw-tooth exposure profile (see Fig. 2 ). Analogue vapor and aerosol monitors can help characterize the degree and impact of the saw-tooth on the process of dosing as well as the chamber's return to a constant exposure.
Dr. Witten's lab may have answered these questions, typically asked of any inhalation study, already -they were simply not addressed at this workshop. We offer our suggestions and our help in support of this important research and to buttress its documentation -JP-8's immunotoxic potential remains an open question. The added information we propose should also support Dr. Kozumbo's goal of a well-developed and informed risk assessment for JP-8.
